Comparison · NCT00496834-sae
Losartan vs Carvedilol: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Losartan vs Carvedilol: serious adverse events. Trial comparisons, record NCT00496834-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00496834-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0495 | 0.0213 | 0.111 | wilson | |
| Risk in group 2 | 0.06 | 0.0278 | 0.125 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0105 | -0.0811 | 0.0587 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.825 | 0.26 | 2.62 | log | |
| Odds ratio, group 1 over group 2 | 0.816 | 0.241 | 2.77 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Losartan than on Carvedilol | 95.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Losartan | Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg / hydrochrolorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochrolorothiazide 25 mg), 24 weeks (Subjects who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who received the investigational drug at least more than once. | 5 | 101 | EG000 |
| Group 2 | Carvedilol | Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or~Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Subjects who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan) and patients who received the investigational drug at least more than once. | 6 | 100 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were recorded from first administration of study drug up to 14 days after the administration of final dose.
Source ClinicalTrials.gov
Trial
- Title
- LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)
- NCT number
- NCT00496834
- Phases
- PHASE4
- Conditions
- Hypertension
- Interventions
- losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ), Comparator: carvedilol (+) hydrochlorothiazide
- Lead sponsor
- Organon and Co
- Results first posted
- 2010-12-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00496834?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00496834-sae